Newsroom

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today its consolidated financial results for the first quarter, ended June 30, 2026, of the current fiscal year ending March 31, 2027 (fiscal 2027). The full document on Mitsubishi Electric’s financial results can be viewed at the following link: www.MitsubishiElectric.com/en/pr Consolidated Financial Results Billions of yen Q1 FY26 Q1 FY27 YoY Revenue 1,312.8 1,497.1 +184.2 114% Adjusted operating profit 93.8 144.3...

PARIS--(BUSINESS WIRE)--Regulatory News: Orano: Activité globalement stable avec des situations contrastées par secteur, EBITDA pénalisé par des arrêts de production Chiffre d’affaires de 2 696 M€, en légère progression de + 2,1 % (p.c.c.), marqué par une bonne performance du secteur Aval et un écoulement moins favorable du carnet de commandes des secteurs Mines et Amont entre les deux périodes. EBITDA en baisse à 595 M€ (contre 727 M€ au 1er semestre 2025) compte tenu d’arrêts de production da...

PARIS--(BUSINESS WIRE)--Orano: 2026 half-year results in line with annual outlook despite circumstantial production stoppages...

TOKYO--(BUSINESS WIRE)--Renesas announced consolidated financial results in accordance with IFRS for the three and six months ended June 30, 2026....

TOKYO--(BUSINESS WIRE)--Renesas will gradually scale down and end manufacturing operations at the Takasaki Factory over the next 2 to 3 years while maintaining R&D functions....

ROTKREUZ, Switzerland--(BUSINESS WIRE)--Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults w...

TOKYO--(BUSINESS WIRE)--Renesas today announced the consolidated financial forecasts for the nine months ending September 30, 2026....

TOKYO--(BUSINESS WIRE)--Renesas today announced the recording of finance income in the three months ended June 30, 2026 (April 1, 2026 to June 30, 2026)....

TOKYO--(BUSINESS WIRE)--Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZenec...

LOS ANGELES--(BUSINESS WIRE)--BE CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Bloom Energy Corporation...